Rocket Lab's Mars Miss: When Reliability Stops Being a Catalyst

Rocket Lab's 94th Electron launch succeeds, but losing a $700M NASA contract to Blue Origin and Neutron delays weigh on the stock, down 59% from highs.

There is a cruel irony in being the company that always delivers: eventually, delivery becomes the baseline, and the market starts asking what you've done lately that's bigger. Rocket Lab is living that paradox right now. The 94th Electron rocket lifted off Thursday from Launch Complex 1 in Mahia, New Zealand, carrying a StriX SAR satellite for Japanese customer Synspective — the eleventh dedicated mission for that client alone. Routine, in other words. And routine, as any trader will tell you, rarely moves a stock.

What did move the stock this week was the opposite of routine: a lost contract. The NASA Mars Telecommunications Network award, worth up to $700 million, went to Blue Origin, not Rocket Lab. The shares slipped 2 percent in the aftermath. For a company positioning itself as a versatile space-services player, losing a marquee government tender stings more than the financials suggest — it was a chance to prove it could play in the big leagues beyond its launch-and-satellites core. That proof didn't materialize.

The Widening Gap Between Operations and Valuation

The operational story, to be fair, remains sturdy. Rocket Lab has now completed 15 launches this year, with 16 more Synspective missions booked through 2030. The backlog hit a record $2.36 billion in the second quarter, and the third quarter has already added over $1 billion in new contracts. Management guides to Q3 revenue between $250 million and $265 million, with GAAP gross margin of 29 to 31 percent. Q2 revenue climbed from $144.5 million to $234.07 million year-over-year, while the net loss narrowed to roughly $49.3 million — still red, but trending in the right direction.

None of that is showing up in the chart. The stock trades around €55.30, roughly 59 percent below its 52-week high of €133.80, and has shed 14 percent over the past month. The secondary source puts the 30-day decline at 16 percent, with the shares sitting 22 percent below their 200-day moving average. Either way, the picture is the same: a company firing on all operational cylinders while the market prices in something darker.

Neutron's Narrowing Window

What the market is pricing, at least in part, is the Neutron question. Founder Peter Beck has conceded that the window for a Neutron launch this year is "narrowing." The new rocket is slated for delivery to its Virginia launch site in the fourth quarter, where it must still undergo integrated testing, static-fire trials, and wet dress rehearsals — a schedule with little margin for error.

There are encouraging signs on the technical front. The "Hungry Hippo" payload fairing has cleared all tests and integration steps, and the company has completed hundreds of ignition tests on the Archimedes engine. Progress is real — it's just not fast enough to fully soothe investor nerves.

Insider Sales, Analyst Divergence, and One Contrarian Buyer

The insider activity adds another layer of texture. CFO Adam Spice has disclosed plans to sell 140,157 shares worth roughly $8.8 million through an automated 10b5-1 plan — a move that barely registered, with the stock actually gaining 1 percent on Wednesday. President Marvin Bradford Clevenger recently sold 15,051 shares for about $1 million. Earlier, COO Frank Klein and General Counsel Arjun Kampani also trimmed positions in late August, though all of these were within pre-arranged plans and hardly constitute alarm bells. Still, of 78 tracked insiders, sellers outnumber buyers — typical for tech, but consistent with a stock trading on short-term visibility.

Analyst sentiment is genuinely split. Berenberg initiated coverage with a Buy and an $83 price target. Bank of America's Ronald Epstein reaffirmed Buy in late August. BTIG, however, remains at Hold. The bulls see operational momentum; the bears see execution risk.

One notable contrarian: Cathie Wood's ARK Invest added over 700,000 shares during this very stretch of Neutron anxiety. It's an ant-cyclical wager worth acknowledging without overinterpreting.

A Sector Under Pressure

Rocket Lab isn't suffering in isolation. Berenberg notes the broader space sector has fallen 53 percent since May before buyers recently stepped back in — AST SpaceMobile jumped 10 percent on an insider purchase and fresh buy recommendation. Rocket Lab's annualized 30-day volatility of 68 percent puts it squarely in this turbulent neighborhood.

The real question, then, isn't whether Rocket Lab can keep launching rockets. It clearly can, week after week. The question is whether operational excellence alone suffices in a market where the largest contracts increasingly flow to larger competitors — and where the company's own next act, Neutron, remains a promise rather than a payload. The lost Mars contract doesn't break the growth story, but it removes a piece of evidence that Rocket Lab could win the kind of prestige awards that would re-rate the stock. For now, the operating substance outweighs the short-term setbacks. But the Neutron clock is ticking louder than management would prefer.